3929 Point Eden Way
United States - Map
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). The company is conducting Phase 3 clinical trials with Pulmaquin in BE; Phase 2b trial with Lipoquin and Pulmaquin in BE. It has also completed a Phase 2a trial with Lipoquin in CF and Phase 2a trial with Lipoquin in BE. The companys proprietary program under development comprises ARD-1600 Inhaled Nicotine, a smoking cessation therapy. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.
|Dr. Igor Gonda Ph.D.,
Chief Exec. Officer, Pres and Exec. Director
|Ms. Nancy E. Pecota ,
Chief Financial Officer, VP of Fin. and Corp. Sec.
|Mr. Juergen Froehlich M.D., MBA, FCPh,
Chief Medical Officer
|Dr. Robert A. Reed Ph.D.,
VP of Regulatory & Quality
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|